Portal de Periódicos da CAPES

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

2012; Elsevier BV; Volume: 23; Issue: 8 Linguagem: Inglês

10.1093/annonc/mdr572

1569-8041

Daniele Santini, Marco Tampellini, Bruno Vincenzi, Toni Ibrahim, Cinzia Ortega, Vladimir Virzì, Nicola Silvestris, Rossana Berardi, Cristina Masini, N. Calipari, Davide Ottaviani, Vincenzo Catalano, Giuseppe Badalamenti, Rocco Giannicola, Francesco� Fabbri, Olga Venditti, Maria Elisabetta Fratto, Calogero Mazzara, Tiziana Pia Latiano, Federica Bertolini, Fausto Petrelli, Azzurra Ottone, C. Caroti, Lisa Salvatore, Alfredo Falcone, Paolo Giordani, Raffaele Addeo, Massimo Aglietta, Stefano Cascinu, Sandro Barni, Evaristo Maiello, Giuseppe Tonini,

Management of metastatic bone disease

BackgroundData are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC.Patients and methodsThis retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes.ResultsMost patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid.ConclusionThis study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting.